SAP stock jumps on DAX strength, with NRF AI push and Jan. 29 earnings in focus

SAP stock jumps on DAX strength, with NRF AI push and Jan. 29 earnings in focus

FRANKFURT, Jan 11, 2026, 19:47 CET — Market closed

  • On Friday, SAP shares closed roughly 2.8% higher in Frankfurt, beating the local blue-chip index.
  • As the new week begins, investors are eyeing European tech for follow-through and monitoring SAP’s latest moves in retail AI.
  • SAP’s quarterly results, due Jan. 29, will be the next major catalyst.

SAP SE shares climbed 2.8%, finishing Friday at 212.35 euros. The stock hit an intraday peak of 214.25 euros, drawing attention heading into the new week. 1

This matters because SAP ranks among the DAX’s largest components and serves as a key indicator for Europe’s enterprise software sector. With markets closed on Sunday, all eyes turn to Monday to see if buyers hold firm and how much risk appetite remains ahead of earnings.

European stocks closed the week at a record high, led by strength in the technology sector. This boost supported large-cap software shares across the board. 2

In Frankfurt, SAP topped the DAX at the close as the index hit a new record high. 3

Over the weekend, SAP unveiled a fresh batch of AI-powered retail tools ahead of NRF 2026 in New York, presenting them as solutions that integrate data, planning, and in-store operations. “Retailers face a landscape where AI is no longer optional,” said Balaji Balasubramanian, SAP’s president and chief product officer for customer experience and consumer industries. 4

The more significant checkpoint is right around the corner. SAP plans to release its fourth-quarter and full-year 2025 results on Jan. 29, followed by a management conference call at 07:00 CET, according to its investor relations calendar. 5

In New York, SAP’s U.S.-listed ADRs climbed to $247.11, marking a roughly 2.6% increase from the previous close, according to market data.

Investors now want clear specifics from SAP on cloud growth and profitability, not just strong top-line numbers. Cloud subscriptions get particular attention—they’re recurring revenue, which usually sticks around longer than one-time licenses.

The AI story plays a role here but it’s a double-edged sword. New features and demos don’t necessarily lead to immediate bookings, and major clients often take a while to implement new modules.

Traders will be watching closely for any incremental customer updates linked to NRF this week and, on a broader scale, whether Europe’s tech rally can withstand volatile macro headlines. The next key date is SAP’s earnings report on Jan. 29, which could shift market expectations.

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Boeing MAX 10 moves a step closer — why industrials ETF XLI and Boeing stock are on Monday’s radar
Previous Story

Boeing MAX 10 moves a step closer — why industrials ETF XLI and Boeing stock are on Monday’s radar

Real Estate Stocks in focus: XLRE, REITs brace for CPI after Trump’s $200 billion mortgage-bond push
Next Story

Real Estate Stocks in focus: XLRE, REITs brace for CPI after Trump’s $200 billion mortgage-bond push

Go toTop